Clinic Roundup

 Lixte Biotechnology Holdings Inc., of East Setauket, N.Y., said the FDA cleared the firm for a Phase I trial of cancer compound LB-100. The company also said it raised $2.5 million to initiate the trial and continue drug discovery research through an offering to holders of warrants for exercising their rights in cash.